Abzena Signs Biologics Supply Pact
Abzena, a Cambridge, UK-based contract biologics manufacturer, and Faron Pharmaceuticals, a Turku, Finland-based biopharmaceutical company, have formed an agreement in which Abzena will manufacture Clevegen, an antibody being developed by Faron for reducing immune suppression in cancer.
Under the agreement, Abzena will produce the master cell bank and manufacture the antibody for clinical development under cGMP. Clevegen was humanized by Abzena using its Composite Human Antibody technology. This is the first product produced using Abzena's humanization technology that will also be manufactured by Abzena following its acquisition of PacificGMP, a San Diego, California-based contract manufacturing organization, in September 2015.
Faron had previously signed an agreement with Selexis, a Plan-les-Ouates, Switzerland-based cell line developer, to obtain cell clones with high Clevegen production. This collaboration has progressed as planned, and the best selected clone will be used by Abzena to produce the master cell bank for Faron.